Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 6/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | F2R | P25116 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25096216 | 0.92 | NCF1 (0.43) | NCF1ACHEHRH3GNAO1GNAI3 | |
| SCHEMBL13240487 | 0.91 | NCF1 (0.41) | NCF1ACHEHRH3GNAO1GNAI3 | |
| SCHEMBL17030786 | 0.86 | NCF1 (0.46) | NCF1ACHEHRH3GNAO1GNAI3 | |
| SCHEMBL24319800 | 0.82 | NCF1 (0.62) | NCF1ACHEHRH3GNAO1GNAI3 | |
| SCHEMBL8740002 | 0.80 | NCF1 (0.54) | NCF1ACHEHRH3GNAO1GNAI3 | |
| SCHEMBL24426052 | 0.79 | NCF1 (0.48) | NCF1ACHEHRH3GNAO1GNAI3 | |
| SCHEMBL14593629 | 0.79 | HTT (0.30) | — | |
| SCHEMBL9130127 | 0.79 | — | — | |
| SCHEMBL13967030 | 0.79 | GNAO1 (0.47) | HRH3GNAO1KCNH2CACNA1I | |
| SCHEMBL15247131 | 0.79 | NCF1 (0.43) | NCF1ACHEHRH3GNAO1GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| US-20210002233-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20200237766-A1 | PKM2 ACTIVATORS IN COMBINATION WITH REACTIVE OXYGEN SPECIES FOR TREATMENT OF CANCER | SUMITOMO PHARMA ONCOLOGY, INC. | 2020-07-30 | — | — | US | disclosed |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-10207996-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-9873709-B2 | Triazolopyridine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873709-B2 | Triazolopyridine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160039838-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-02-11 | — | — | US | disclosed |
| US-20150344436-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2015-12-03 | — | — | US | disclosed |
| US-9169240-B2 | Ketone linked benzothiazole inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150239879-A1 | KETONE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-27 | — | — | US | disclosed |
| US-8957075-B2 | O-GlcNAc transferase inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-02-17 | — | — | US | disclosed |
| US-20130196960-A1 | Cannabinoid Receptor Agonists | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | NCF1 2185/4885ACHE 2310/4885HRH3 1610/4885 |
| US-20160039838-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | WNK1, ABL1, NEK4 | NCF1 901/4885ACHE 3925/4885HRH3 1820/4885 |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | TYRO3, LCK, LTK | NCF1 1466/4885ACHE 4389/4885HRH3 887/4885 |
| US-20130196960-A1 | Cannabinoid Receptor Agonists | CNR2, CNR1, GPR18 | NCF1 2963/4885ACHE 1810/4885HRH3 295/4885 |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | NCF1 2185/4885ACHE 2310/4885HRH3 1610/4885 |
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | OGA, OGT, UGGT1 | NCF1 1730/4885ACHE 389/4885HRH3 4616/4885 |
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | NCF1 2866/4885ACHE 4012/4885HRH3 258/4885 |
| US-10207996-B2 | PKM2 modulators and methods for their use | PDK1, PDK2, PKM | NCF1 4738/4885ACHE 3589/4885HRH3 2625/4885 |
| US-20200237766-A1 | PKM2 ACTIVATORS IN COMBINATION WITH REACTIVE OXYGEN SPECIES FOR TREATMENT OF CANCER | PDK1, PDK2, PCK2 | NCF1 1898/4885ACHE 4765/4885HRH3 4260/4885 |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | NCF1 2908/4885ACHE 2929/4885HRH3 1770/4885 |
| US-20210002233-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | NCF1 4738/4885ACHE 3589/4885HRH3 2625/4885 |
| US-20150344436-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | NCF1 4738/4885ACHE 3589/4885HRH3 2625/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | NCF1 2185/4885ACHE 2310/4885HRH3 1610/4885 |
| US-20150239879-A1 | KETONE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LPL, LIPE | NCF1 1999/4885ACHE 573/4885HRH3 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.